E 7820

Drug Profile

E 7820

Alternative Names: E-7820

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Class Antineoplastics; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Integrin alpha2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 13 Feb 2017 Phase I/II development for Solid tumours is ongoing in USA
  • 13 Feb 2017 Eisai completes a phase II trial in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada (PO) (NCT00309179)
  • 22 Dec 2015 Phase II development for Colorectal cancer is ongoing in USA and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top